Geranylgeraniol for MVK deficiency trial
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a natural supplement called geranylgeraniol can help people with mevalonate kinase deficiency (a rare metabolic condition). If you are 12 or older and have this diagnosis, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older
- You have a genetic diagnosis of mevalonate kinase deficiency (MVK deficiency)
- You are in generally good health, aside from the MVK deficiency
- Your liver function tests are normal
- You are willing to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a supplement called geranylgeraniol (GG) can improve muscle health. It is looking for physically active adults who are willing to follow specific dietary rules and avoid certain foods and supplements during the study.
This study tests if a medicine called Glycerol Phenylbutyrate (RAVICTI) is safe and helpful for children and young adults with a specific type of PDH deficiency, a rare genetic condition affecting energy use. If you qualify, you may get a new treatment option.
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
This trial tests whether a supplement called NMN is safe and well-tolerated in children and adults with a rare genetic condition called DHDDS-CDG. NMN may help support cellular energy and protein production, which are affected by this condition.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This early-stage trial tests VGN-R09b, a gene therapy, given to children with AADC deficiency who are not doing well on standard medicines. It aims to improve symptoms and quality of life by addressing the underlying cause of AADC deficiency.
Hear when a new Mevalonate Kinase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.